B7-1/CD80 Chimeric Monoclonal Antibody

<strong>B7-1/CD80 Chimeric Monoclonal Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2017702_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Activation B7-1 Antigen, B7, B7-1, BB1, CD28LG, CD28LG1, CTLA-4 Counter-receptor B7.1, LAB7, T-lymphocyte Activation Antigen CD80_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Wyss-Coray T, Mauri-Hellweg D, Baumann K, Bettens F, Grunow R, Pichler WJ. The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions Eur J Immunol. 1993 Sep;23(9):2175-80._x000D_ 2: Zhang H, Wen K, Huang JL, Hu MZ, Shen JS, Pan ZM, Jiao XA. [The adjuvant effect of chimeric flagellin fliC/esat] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Apr;27(4):377-81._x000D_ 3: Nishibori S, Kaneko MK, Nakagawa T, Nishigaki K, Kato Y, Igase M, Mizuno T. Development of anti-feline PD-1 antibody and its functional analysis Sci Rep. 2023 Apr 24;13(1):6420._x000D_ 4: Kalim M, Ali H, Rehman AU, Lu Y, Zhan J. Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody Front Immunol. 2022 Oct 21;13:1012499._x000D_ 5: Phakham T, Boonkrai C, Wongtangprasert T, Audomsun T, Attakitbancha C, Saelao P, Muanwien P, Sooksai S, Hirankarn N, Pisitkun T. Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development Sci Rep. 2022 Oct 22;12(1):17792._x000D_ 6: Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA Cancer Immunol Res. 2019 Jul;7(7):1120-1134._x000D_ 7: Narula J, Petrov A, O'Donnell SM, Ditlow C, Pieslak I, Dilley J, Chen F, Khaw BA. Gamma imaging of atherosclerotic lesions: the role of antibody affinity in in vivo target localization J Nucl Cardiol. 1996 May-Jun;3(3):231-41._x000D_ 8: Nakagawa T, Kijima N, Hasegawa K, Ikeda S, Yaga M, Wibowo T, Tachi T, Kuroda H, Hirayama R, Okita Y, Kinoshita M, Kagawa N, Kanemura Y, Hosen N, Kishima H. Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy Neurooncol Adv. 2022 Nov 15;5(1):vdac177._x000D_ 9: Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities Transplantation. 2007 Feb 15;83(3):304-13._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/29040754">10: Hua CK, Gacerez AT, Sentman CL, Ackerman ME. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6 Protein Eng Des Sel. 2017 Oct 1;30(10):713-721. </a>_x000D_ _x000D_ <strong>Products Related to B7-1/CD80 Chimeric Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>